The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:7f7cd2f7fdebaec69f7d8b978a81c78b]
Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:7f7cd2f7fdebaec69f7d8b978a81c78b]
Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
Bio2RDF identifier
7f7cd2f7fdebaec69f7d8b978a81c78b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7f7cd2f7fdebaec69f7d8b978a81c78b
measure [clinicaltrials_vocabulary:measure]
The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb)
time frame [clinicaltrials_vocabulary:time-frame]
description
Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
identifier
clinicaltrials_resource:7f7cd2f7fdebaec69f7d8b978a81c78b
title
The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks
@en
type
label
The primary efficacy endpoint ...... cd2f7fdebaec69f7d8b978a81c78b]
@en